IBCSG Central Pathology Office and Laboratory at European Institute of Oncology
IBCSG Central Pathology Office and Laboratory at European Institute of Oncology is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
IBCSG 67-22 PREcoopERA: A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The trial randomized 231 patients at 33 centers in six countries between 25 January 2024 and 15 July 2025, exceeding the planned randomization of 220 patients.
- Of 231 randomized patients, 226 initiated window-of-opportunity treatment, 216 had paired biopsies, and 204 met criteria for the primary analysis population.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After Treatment with an Aromatase Inhibitor (CAPItello-291)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
POLAR: A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for IBCSG Central Pathology Office and Laboratory at European Institute of Oncology?
The 2026-10-09 snapshot links IBCSG Central Pathology Office and Laboratory at European Institute of Oncology to 3 distinct CTIS trials. Recorded services include Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for IBCSG Central Pathology Office and Laboratory at European Institute of Oncology?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to IBCSG Central Pathology Office and Laboratory at European Institute of Oncology conducted?
The linked trials record locations in 10 countries, including Spain, France, Hungary, Italy, Germany. These are trial locations, not confirmed office locations or countries where IBCSG Central Pathology Office and Laboratory at European Institute of Oncology delivered services.
What can this page tell me about IBCSG Central Pathology Office and Laboratory at European Institute of Oncology's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under IBCSG Central Pathology Office and Laboratory at European Institute of Oncology. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- IBCSG Central Pathology Office and Laboratory at European Institute of Oncology